Company: CDLX
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001666071-25-000159
Chunk: 101

Company: Cardlytics, Inc.
Filing Date: 2025-11-05
Form: 10-Q
Item: Item 1
Chunk 101
---
994 $10 $1,385,465 $(3,628)$(1,323,141)$58,706 Stock-based compensation— — 7,673 — — 7,673 Settlement of restricted stock812 — — — — — Issuance of common stock pursuant to the 2018 ESPP (as defined below)— — — — — — Other comprehensive income— — — 1,590 — 1,590 Net Loss— — — — (72,673)(72,673)Balance – September 30, 202553,806 $10 $1,393,138 $(2,038)$(1,395,814)$(4,704)

See notes to the condensed consolidated financial statements6

Nine Months Ended September 30, 2024:

  AdditionalPaid-InCapitalAccumulatedOtherComprehensiveIncome (Loss)AccumulatedDeficitTotal Common Stock SharesAmountBalance – December 31, 202339,728 $9 $1,243,594 $2,467 $(1,111,272)$134,798 Exercise of common stock options3 — 5 — — 5 Stock-based compensation— — 35,396 — — 35,396 Settlement of restricted stock2,869 — — — — — Issuance of common stock, net of issuance costs - ATM Offering Program (as defined below)3,908 — 48,151 — — 48,151 Issuance of common stock, net of issuance cost3,592 — 27,451 — — 27,451 Issuance of common stock pursuant to the 2018 ESPP (as defined below)242 — 1,461 — — 1,461 Termination of capped calls related to 2020 Convertible Senior Notes— — 115 — — 115 Other comprehensive loss— — — (3,965)— (3,965)Net Loss— — — — (173,715)(173,715)Balance – September 30, 202450,342 $9 $1,356,173 $(1,498)$(1,284,